SalaryGuide
SalariesCompaniesJobs
AboutPricingBlogFor Employers

Marketing jobs

3 marketing jobs

12 days ago

HCP Marketing Director - Enzomenib

Sumitomo Pharma America, Inc.

Marlborough, MA (Remote)Full time$196K/yr – $245K/yr
3 weeks ago

Marketing Associate Director, MYFEMBREE

Sumitomo Pharma America, Inc.

Marlborough, MA (Remote)Full time$171K/yr – $214K/yr
3 months ago

Associate Director, Marketing Analytics - Prostate Cancer

Sumitomo Pharma America, Inc.

Marlborough, MA (Hybrid)Full time$166K/yr – $207K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs

HCP Marketing Director - Enzomenib

Sumitomo Pharma America, Inc.

Marlborough, MA (Remote)

$196K/yr - $245K/yrIn-houseFull-timeDirector/executive10+ years exp.
12 days ago

Marketing Associate Director, MYFEMBREE

Sumitomo Pharma America, Inc.

Marlborough, MA (Remote)

$171K/yr - $214K/yrIn-houseFull-timeDirector/executive8+ years exp.
3 weeks ago

Associate Director, Marketing Analytics - Prostate Cancer

Sumitomo Pharma America, Inc.

Marlborough, MA (Hybrid)

$166K/yr - $207K/yrIn-houseFull-timeSenior level8+ years exp.
3 months ago
Sumitomo Pharma America, Inc.

HCP Marketing Director - Enzomenib

Marlborough, MA (Remote)

$196K/yr – $245K/yrDirector/Executive10+ years expFull time

Posted 12 days ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Own and drive the HCP marketing strategy for Enzomenib, translating complex clinical data into compliant, differentiated messaging and leading cross‑functional execution across materials, digital content, and field engagement.

  • Lead development of HCP strategy, messaging, and tactical plan
  • Align with Sales, Medical Affairs, and cross‑functional partners to execute campaigns and materials
  • Translate AML/hematology data into compelling, compliant messaging for diverse HCP stakeholders

Job Description

Responsibilities

  • Lead development and execution of the HCP marketing strategy for Enzomenib, aligned with the overall brand strategy, business objectives, and commercial priorities.
  • Own the HCP messaging approach and ensure consistent positioning across promotional materials, peer-to-peer initiatives, field resources, congress activities, and digital channels.
  • Translate complex AML clinical and scientific data into compelling, compliant, and differentiated messaging for hematologists, leukemia specialists, transplant physicians, advanced practice providers, and other relevant HCP stakeholders.
  • Partner with the Executive Director to refine brand positioning, HCP engagement priorities, and the tactical plan.
  • Develop branded promotional resources, sales tools, digital content, and educational materials that support field engagement and customer communication.
  • Lead agency partners through strategy development, content creation, revisions, production, approval, and deployment.
  • Manage projects from concept through execution while maintaining quality, scientific accuracy, compliance, timelines, and budget discipline.
  • Own routine HCP marketing operations, including project plans, status meetings, material updates, document routing, budget tracking, invoice review, vendor coordination, and cross-functional follow-up.
  • Prepare materials and submissions for Promotional Review Committee review; consolidate feedback, manage revisions, and ensure approved content is deployed accurately and on time.
  • Maintain current inventories of promotional materials and coordinate updates, expiration management, field communications, and executional details.

Requirements

  • Bachelor's degree in a related field required; advanced degree such as MBA, PharmD, MS, or equivalent preferred.
  • Minimum 10 years of relevant experience in biotech or pharmaceutical industry with Bachelor’s Degree
  • Minimum 5 years Oncology experience required; hematology experience strongly preferred.
  • Must have previous experience developing and executing HCP marketing strategies for specialty products

Preferred

  • Experience supporting a pre-launch or launch-stage oncology product preferred.
  • Demonstrated success translating clinical data into effective promotional messaging and customer engagement tactics.
  • Experience working with academic medical centers, oncology networks, and key opinion leaders preferred.
  • Strong understanding of AML treatment paradigms and hematology market dynamics preferred.
  • Experience with promotional review processes, agency management, budget ownership, and tactical execution required.

Benefits

  • Base salary is part of our total rewards package which also includes the opportunity for merit-based salary increases, short incentive plan participation, eligibility for our 401(k) plan, medical, dental, vision, life and disability insurances and leaves provided in line with your work state. Our robust time-off policy includes flexible paid time off, 11 paid holidays plus additional time off for a shut-down period during the last week of December, 80 hours of paid sick time upon hire and each year thereafter.

Sumitomo Pharma America, Inc.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in oncology, urology, women’s health, rare disease, cell and gene therapies and CNS. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.Community Guidelines: https://www.us.sumitomo-pharma.com/social-media/index.html

Founded in 2023
Marlborough, Massachusetts, USA
1.1K employees (27 in marketing)

Salaries

Posted range

$196K/yr – $245K/yr

Taken straight from the job posting.

See all Sumitomo Pharma America, Inc. salaries

Marketing Team

Marketing Team Size
27 (2% of company)
Median Tenure
3.3 years
Marketing Roles Posted (Last 30 Days)
2

Traffic Signals

Monthly Visitors
21.1K
Traffic Source Mix
Search
45.9%
Direct
41.2%
Referral
8%
Social
2.9%
Paid
1.8%

Headcount Trend

Current headcount: ~1.1K

Recent News

Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
Dec 8, 2025 • WV News
Sumitomo Pharma : Posted Conference on Q2 FY2025 Financial Results
Nov 7, 2025 • MarketScreener
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
Jul 30, 2025 • PR Newswire
Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA®
Jun 30, 2025 • PR Newswire
Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis
Jun 12, 2025 • PR Newswire
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio
Jun 5, 2025 • Yahoo Finance
Knight Therapeutics and Sumitomo Pharma enter into
Jun 5, 2025 • GlobeNewswire
Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting
Apr 29, 2025 • PR Newswire
Sumitomo Pharma’s Comeback Story: Reinventing a Century-Old Giant in a Post-Patent Era
Apr 22, 2025 • geneonline.com
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
Apr 14, 2025 • PR Newswire
Sumitomo Pharma Sues to Block Two Copies of Gemtesa Bladder Drug
Mar 28, 2025 • Bloomberg Law News
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Jan 2, 2025 • Physician's Weekly
Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
Dec 27, 2024 • Indian Pharma Post
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
Dec 23, 2024 • PR Newswire
Sumitomo Pharma America and Actor Holly Robinson Peete Encourage People with Overactive Bladder to Speak Up and Seek Treatment
Dec 3, 2024 • PR Newswire

Links

LinkedInX (Twitter)